Your browser doesn't support javascript.
loading
Liver transplantation for alpha 1 antitrypsin deficiency (A1ATD) using a heterozygous donor: Outcomes and review of the literature.
Sood, Vikrant; Lee, Eliza J; Raghu, Vikram; Reyes-Mugica, Miguel; Salgado, Claudia M; Squires, James; Mazariegos, George.
Afiliação
  • Sood V; Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Dehli, India.
  • Lee EJ; Department of Surgery, Pediatric Transplant Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Raghu V; Division of Pediatric Gastroenterology, Department of Pediatrics, University of Pittsburgh Medical Center Pittsburgh Children's Hospital, Pittsburgh, Pennsylvania, USA.
  • Reyes-Mugica M; Department of Pathology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Salgado CM; Department of Pathology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Squires J; Division of Pediatric Gastroenterology, Department of Pediatrics, University of Pittsburgh Medical Center Pittsburgh Children's Hospital, Pittsburgh, Pennsylvania, USA.
  • Mazariegos G; Division of Transplant Surgery, Department of Surgery, University of Pittsburgh Medical Center Pittsburgh Children's Hospital, Pittsburgh, Pennsylvania, USA.
Pediatr Transplant ; 27(4): e14488, 2023 06.
Article em En | MEDLINE | ID: mdl-36808684
ABSTRACT

INTRODUCTION:

Alpha 1 antitrypsin deficiency (A1ATD) accounts for 21% of all pediatric liver transplants due to metabolic disease in the western world. Donor heterozygosity has been evaluated in adults but not to a recipient with A1ATD.

METHODS:

The data of patient were retrospectively analyzed and a literature review performed.

RESULTS:

We present a unique case of living related donation from a A1ATD heterozygote female to a child for decompensated cirrhosis due to A1ATD. In the immediate postoperative period, the child had low-alpha 1 antitrypsin levels, but these normalized by 3 months posttransplant. He is currently 19 months post-transplant with no evidence of recurrent disease.

CONCLUSION:

Our case provides initial evidence that A1ATD heterozygote donors may be safely used for pediatric patients with A1ATD, thus expanding the donor pool.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Alfa 1-Antitripsina / Transplante de Fígado / Doadores Vivos / Deficiência de alfa 1-Antitripsina / Heterozigoto Limite: Child / Female / Humans / Male Idioma: En Revista: Pediatr Transplant Assunto da revista: PEDIATRIA / TRANSPLANTE Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Alfa 1-Antitripsina / Transplante de Fígado / Doadores Vivos / Deficiência de alfa 1-Antitripsina / Heterozigoto Limite: Child / Female / Humans / Male Idioma: En Revista: Pediatr Transplant Assunto da revista: PEDIATRIA / TRANSPLANTE Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia